SCHEMBL4070975

SCHEMBL4070975

COC(=O)c1cc(-n2c(=O)n(C)c(=O)n(C)c2=O)c(F)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.39
HPGD P15428 3/20 0.38
MAPT P10636 3/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 5/20 0.37
HTT P42858 2/20 0.37
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA3 P34903 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
POLB P06746 1/20 0.35
APEX1 P27695 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GUSB P08236 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HSD17B10 Q99714 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253181 0.91 GAA (0.37) GAAHPGDMAPTLMNASMN1; SMN2
SCHEMBL9139546 0.89 GAA (0.37) GAAHPGDMAPTLMNASMN1; SMN2
SCHEMBL22745804 0.86 MAPT (0.36) GAAHPGDMAPTLMNASMN1; SMN2
SCHEMBL24152095 0.86 LMNA (0.38) GAAHPGDMAPTLMNASMN1; SMN2
SCHEMBL29938165 0.85 NOTUM (0.38) HPGDMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL24151268 0.85 NOTUM (0.38) HPGDMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL30704867 0.83 GAA (0.36) GAAHPGDMAPTLMNASMN1; SMN2
SCHEMBL27559360 0.83 GAA (0.36) GAAHPGDMAPTLMNASMN1; SMN2
SCHEMBL9135270 0.81 P2RX3 (0.36) GAAHPGDMAPTLMNASMN1; SMN2
SCHEMBL9706633 0.81 HPGD (0.34) GAAHPGDMAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1226127-B1 SUBSTITUTED PHENYL SULFAMOYL CARBOXAMIDES BASF SE (DE) 2009-07-01 EP disclosed
US-6849618-B2 Uracil substituted phenyl sulfamoly carboxamides BASF AKTIENGESELLSCHAFT (DE) 2005-02-01 US disclosed
US-20040220172-A1 Herbicidal compositions for the desiccation/ defoliation of plants CARLSEN MARIANNE 2004-11-04 US disclosed
US-6689773-B2 HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 2004-02-10 US disclosed
US-20030224941-A1 Uracil substituted phenyl sulfamoyl carboxamides CARLSEN MARIANNE (US) 2003-12-04 US disclosed
US-6534492-B2 Herbicidal phenylsulfamoyl carboxamides BASF AKTIENGESELLSCHAFT (DE) 2003-03-18 US disclosed
CN-1383425-A Uracil substituted phenyl sulfamoyl carboxamides BASF AG (DE) 2002-12-04 CN disclosed
EP-1226127-A2 URACIL SUBSTITUTED PHENYL SULFAMOYL CARBOXAMIDES BASF AKTIENGESELLSCHAFT (DE) 2002-07-31 EP disclosed
US-20020045550-A1 Uracil substituted phenyl sulfamoyl carboxamides INTELLECTUAL PROPERTY DEPARTMENT BASF AKTIENGESELLSCHAFT (DE) 2002-04-18 US disclosed
WO-2001083459-A2 URACIL SUBSTITUTED PHENYL SULFAMOYL CARBOXAMIDES BASF AKTIENGESELLSCHAFT (DE) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045550-A1 Uracil substituted phenyl sulfamoyl carboxamides CCNH, CBR3, UNG GAA 1530/4885HPGD 2641/4885MAPT 4524/4885
US-20030224941-A1 Uracil substituted phenyl sulfamoyl carboxamides CCNH, CBR3, UNG GAA 1530/4885HPGD 2641/4885MAPT 4524/4885
US-20040220172-A1 Herbicidal compositions for the desiccation/ defoliation of plants CBR3, HDHD5, DDAH1 GAA 1407/4885HPGD 1999/4885MAPT 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.